CVS HIV Headline News News Icon
Home Customer Care Enroll Now Free Info Kit
Today's HIV Headlines




 
search

ProCare

Enroll In CVS ProCare

FREE Info Kit

Provide your confidential contact info and we will call your to answer your questions! Name:

Phone:

Best Time To Call:

A PharmaCare representative will call to assist you and answer your questions. We will leave a brief message if you are unavailable at the time of our call.


Pharmacy

Special Callout
Call Today
1-800-238-7828

Pharmacy


E-Mail this Article to a friend!Powered by ReutersPharmacy
Pharmacy

Treatment during primary HIV infection restricts viral evolution

Last Updated: 2001-04-10 12:00:53 EDT (Reuters Health)

WESTPORT, CT (Reuters Health) - HIV DNA replication and mutation is restricted in subjects who initiate treatment with highly active antiretroviral therapy (HAART) during primary infection, according to results of a Swedish study.

Dr. Anders Sonnerborg of the Karolinska Institutet in Stockholm and associates studied viral evolution and HIV-1 DNA dynamics in 16 subjects with primary HIV-1 infection, 9 of whom initiated HAART within a median of 11 days after onset of symptoms.

The investigators conducted extensive sequential cloning and sequence analysis of the V3 region in three HAART-treated subjects and one untreated subject. "In the treated subjects a continuous decline in the proviral load was found, corresponding to a half-life of about 6 months," Dr. Sonnerborg's group reports in the March 20th issue of AIDS Research and Human Retroviruses. In all four subjects, high intrasubject sequence similarity was observed in the founder virus populations.

However, the three treated subjects exhibited a limited increase in viral divergence and diversity over time. In two of three treated subjects, limited sequence evolution of no more than three mutations was observed by up to 6 months.

The researchers also observed that a continuous decline in viral slope correlated with the decay rate of human memory T lymphocytes.

Dr. Sonnerborg's group suggests that early treatment may result in a smaller pool of infected CD4+ T cells and may prevent HIV-1 from entering compartments resistant to drug penetration.

AIDS Res Hum Retroviruses 2001;17:409-416.

-Westport Newsroom 203 319 2700


 
Pharmacy
 
Copyright 2001 Reuters Limited. All rights reserved. Republication or redistribution of Reuters Limited content, including by framing or similar means, is expressly prohibited without prior written consent of Reuters Limited. Reuters Limited shall not be liable for any error or delays in the content, or for any actions taken in reliance thereon.

Pharmacy Back To HIV Wellness CenterPharmacy


CVS ProCare -Specialized Pharmacy CarePharmacyEnroll Today!

Home | Customer Care | Enrollment | Free Information Kit | Site Map | Privacy | Back to Top

A MEMBER OF THE CVS FAMILY OF CARE
 
© PharmaCare 2001 | Content Last Modified .